Manchester Institute of Biotechnology

What Manchester Institute of Biotechnology does

The Manchester Institute of Biotechnology (MIB) is an interdisciplinary research institute within the University of Manchester, established in 2006 to integrate biology, chemistry, engineering, and computational sciences for industrial and biomedical applications. The institute operates across four research themes (industrial biotechnology, biomedical biotechnology, molecular engineering, and synthetic biology/biomanufacturing) and houses more than 50 research groups with over 400 staff and students, supported by national facilities including the Future BRH, IBIC, SEP Hub, and C-Loop programmes. MIB's core technical capabilities span enzyme engineering, 3D cell culture scaffolds, cryopreservation (ICEP technology licensed to CryoLogyx), bioprocess design, and AI/machine learning applied to text mining (NaCTeM), enzyme discovery, and generative biomolecule design.

MIB's business model is fundamentally grant-funded academic research, supplemented by technology licensing and contract research with industrial partners. The disclosed active grant portfolio exceeds £100M, sourced primarily from UK research councils (BBSRC, EPSRC), ARIA, the Bill & Melinda Gates Foundation, and aligned industry partners including AstraZeneca and Equinor. Commercial output is realized through spin-out formation and IP licensing: identified spin-outs include Imperagen (Digital Enzyme Evolution), C3 Biotechnologies, C4X Discovery, Holiferm, Dekiln, Deuterose, and Sebomix, with prior spin-out Manchester BIOGEL acquired by Cell Guidance Systems in 2023. Customers span academic peers, biopharma and energy industry partners, government funders, and policy stakeholders. AI/ML is embedded across multiple research themes and underpins the Imperagen platform, NLP capabilities via NaCTeM, ML-driven cryoprotectant discovery, light-powered enzyme design, the BIOAID industrial biocatalysis programme, and high-throughput screening pipelines delivering claimed 1000x speedups.

Name

Manchester Institute of Biotechnology

Legal name

Manchester Institute of Biotechnology

Website

https://mib.ac.uk

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

The Manchester Institute of Biotechnology is a University of Manchester research institute running 50+ interdisciplinary groups across biology, chemistry, engineering, and AI, with £100M+ in active grants and a portfolio of spin-outs serving biopharma, energy, and industrial biotechnology customers.

Ownership category

akta.pro rank

Product category

Industrial Biotechnology Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Engineering, Accounting, Research, Management (8700)

akta.pro primary industry

Microbiology & Infectious Disease Testing (Trial Support) (HLAGAEAF)

Keywords

• Industrial biotechnology research
• Enzyme engineering
• Biocatalysis development
• Synthetic biology platforms
• Biomanufacturing research

Headquarters

HQ city

Manchester

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Research Grants and Funding: The institute operates as a university research centre funded primarily through competitive research grants from UK government agencies (BBSRC, EPSRC, ARIA), charitable foundations (Wellcome Trust, Gates Foundation, Chan Zuckerberg Initiative), and international funding bodies.
2. Technology Licensing: The institute licenses proprietary technologies developed by its researchers to industrial partners for commercial application, generating royalty income.
3. Research Collaboration and Contract Research: Collaborative research projects with industry partners (e.g., pharmaceutical, chemicals, materials companies) where partners co-fund or contract research activities.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

The Manchester Institute of Biotechnology (MIB) is an interdisciplinary research institute within The University of Manchester that conducts research in industrial biotechnology, with focus areas spanning engineering biology, enzyme engineering, biocatalysis, synthetic biology, structural biology, computational biology and biomanufacturing. It delivers this through collaborative research with industry and academic partners, technology licensing, doctoral training programmes, and a free online MOOC in industrial biotechnology hosted on Coursera.

Product overview

The Manchester Institute of Biotechnology (MIB) is a research institute, not a product company. It operates as a technology and research powerhouse with multiple spin-out companies and commercial products. The portfolio includes: Manchester BIOGEL (PeptiGel) - performance hydrogels for biotech/pharma; C3 Biotechnologies - biofuels from waste; C4X Discovery - NMR-based drug discovery; Imperagen - AI-powered enzyme engineering; Holiferm - sustainable biosurfactants; plus educational offerings (Industrial Biotechnology MOOC via Coursera) and doctoral training programmes. MIB also houses major research centres including CADDA, COEBP, Future Biomanufacturing Research Hub, IBIC, ICED, MBEC, MBCCMS, and NaCTeM, supported by world-class core research facilities for automation, spectroscopy, NMR, mass spectrometry, and structural biology.

Differentiator

Problem solved

Functional benefit

Brands

• Manchester BIOGEL: Performance hydrogels for pharmaceutical, biotechnology, and cosmetic industries as well as academia. Formerly known as PeptiGelDesign, founded in 2013 by Drs Aline Miller and Alberto Saiani.
• Imperagen
• C3 Biotechnologies
• C4X Discovery
• Holiferm
• Dekiln

Products and services

• Manchester BIOGEL (PeptiGel) Spin-out commercialising peptide-based hydrogel products (PeptiGel) for 3D cell culture, regenerative medicine and biomedical applications.
• Imperagen Spin-out offering enzyme engineering services and biocatalysis solutions using a proprietary computational/digital enzyme evolution platform for industrial partners.
• C3 Biotechnologies Spin-out developing biofuels and bioethanol production technologies from waste and sustainable feedstocks.
• C4X Discovery Spin-out providing drug discovery services using molecular conformation analysis and computational chemistry approaches.
• Holiferm Spin-out producing sustainable biosurfactants (sophorolipids) as alternatives to petrochemical surfactants for personal care and cleaning applications.
• Dekiln Spin-out manufacturing advanced ceramic materials developed from MIB research, established during the COVID-19 pandemic.
• Deuterose Spin-out supplying deuterated and isotopically-labelled compounds for research and industrial applications.
• Sebomix Ltd Spin-out developing diagnostic tests using sebum biomarkers for skin and systemic disease detection.
• Industrial Biotechnology MOOC Free open-access online course covering the fundamentals of industrial biotechnology, delivered on the Coursera platform for global learners.
• Doctoral Training Programmes Funded doctoral (PhD) training programmes in biotechnology, including the Manchester BBSRC Doctoral Training Partnership, providing postgraduate research training.
• Research Facilities and Core Services Shared state-of-the-art research infrastructure including mass spectrometry, NMR, X-ray crystallography, bio-automation, and protein production facilities, accessible to internal researchers and external collaborators.
• Centre for Advanced Diagnostic Development and Application (CADDA) Research centre within MIB focused on the development and application of advanced diagnostics, including biomarker discovery and diagnostic platform technologies.
• Centre of Excellence in Biopharmaceuticals (COEBP) Centre of Excellence delivering biopharmaceutical research, training and industry engagement within MIB.
• Future Biomanufacturing Research Hub (FBRH) National research hub advancing sustainable biomanufacturing processes for chemicals and pharmaceuticals, funded through UK Research and Innovation's Strength in Places Fund.
• Industrial Biotechnology Innovation Catalyst (IBIC) Catalyst programme connecting MIB's research capabilities with industry to translate industrial biotechnology discoveries into commercial applications.
• International Centre for Enzyme Design (ICED) International research centre dedicated to the design of new enzymes, supported by ARIA and involving international collaborators.
• Manchester Biomolecule Engineering Centre (MBEC) Centre providing biomolecule engineering training, research and industry engagement, including the Advanced Training Programme delivered jointly with Syngenta and industrial partners.
• Michael Barber Centre for Collaborative Mass Spectrometry (MBCCMS) Centre delivering collaborative mass spectrometry services and research for proteomics, metabolomics and biomolecular analysis.
• National Centre for Text Mining (NaCTeM) National centre providing text mining, natural language processing and bioinformatics services applied to biomedical and biotechnology research.

Quantifiable outcome

• 23-fold increase in citramalate production using design-of-experiment approach with cyanobacteria, achieving 6.35 g/L in 2-litre photobioreactors
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Partnerships

17 partnerships are on record, tiered core and notable.

• ImperagencoreStrategic or Co-development Partner · 1 January 2021Techbio spin-out established in 2021, focused on accelerating enzyme engineering through Digital Enzyme Evolution™ technology combining AI protein design with automation. Raised £5M seed funding in 2026 from PXN Ventures, IQ Capital, and Northern Gritstone.
• Manchester BIOGELnotableStrategic or Co-development Partner · 1 January 2013Spin-out company founded in 2013 by Drs Aline Miller and Alberto Saiani from MIB to commercialise performance peptide-based hydrogels (PeptiGels®) for pharmaceutical, biotechnology, and cosmetic industries. Acquired by Cell Guidance Systems in 2023.
• C3 BiotechnologiesnotableStrategic or Co-development PartnerSpin-out company developing sustainable biofuels and bio-based fuel technologies (bio-ethanol from CO2, LPG from waste, aviation fuel precursors). MIB Founding Director Nigel Scrutton is a Founding Director. Works with Future BRH for techno-economic analysis and environmental impact assessment.
• HolifermnotableStrategic or Co-development PartnerSpin-out developing sustainable biosurfactant manufacturing processes using continuous fermentation and integrated gravity separation technology for large-scale production.
• CryoLogyxnotableStrategic or Co-development PartnerIndustry partner collaborating with MIB researchers (led by Prof. Matthew Gibson) on development of groundbreaking 'blood on demand' cryopreservation technology using novel polyampholyte-based cryoprotectant formulations.
• Equinor ASAcoreStrategic or Co-development PartnerGlobal energy company collaborating with University of Manchester researchers on a project to study how microbes in deep underground CO2 storage sites could impact carbon capture and storage success.
• Future Biomanufacturing Research Hub (Future BRH)coreStrategic or Co-development PartnerEPSRC/BBSRC funded national biomanufacturing accelerator coordinating UK academic, HVM Catapult, and industrial capabilities. MIB (led by Prof. Nigel Scrutton) is a key founding partner, coordinating the complete biomanufacturing innovation pipeline.
• Industrial Biotechnology Innovation Catalyst (IBIC)coreStrategic or Co-development PartnerA consortium of higher education institutions, businesses, and organisations across the north-west of England focused on building the industrial biotechnology pipeline from lab to life.
• Sustainable Engineering Plastics (SEP) HubnotableStrategic or Co-development PartnerEPSRC £13.6M Manufacturing Research Hub with Manchester, University of Warwick, and UCL, engaging 60+ industry partners (Siemens, Polestar, Biffa, Vita) to improve sustainability of engineering plastics.
• Carbon-Loop Sustainable Biomanufacturing Hub (C-Loop)notableStrategic or Co-development PartnerEPSRC £14M Hub led by University of Edinburgh with Manchester, Nottingham, UCL, and Imperial. MIB researchers will explore how engineered microbial systems can convert carbon-rich industrial waste into high-value products including cosmetics, material precursors and solvents.
• Leeds UniversitynotableStrategic or Co-development PartnerCollaborating with Prof. Matthew Gibson at MIB on the 'blood on demand' cryopreservation research led by Dr Fraser Macrae from Leeds.
• International Centre for Enzyme Design (ICED)notableStrategic or Co-development PartnerInternational partnership bringing together world leaders in computational protein design, enzyme engineering, and industrial biocatalysis to establish integrated computational and experimental programmes for reliable enzyme design.
• BBSRC North West Doctoral Training PartnershipnotableStrategic or Co-development PartnerFully-funded doctoral training programme in bioscience in partnership with BBSRC and University of Liverpool, providing interdisciplinary bioscientist training.
• IBioIC Collaborative Training PartnershipnotableStrategic or Co-development PartnerIndustrial Biotechnology Innovation Catalyst (IBioIC) funds four-year studentships leading to PhD degrees, providing students with industry-ready skills for the biotechnology sector.
• A*STAR SingaporenotableStrategic or Co-development PartnerFour-year funded dual PhD programme enabling postgraduate researchers to spend two years at The University of Manchester and two years at an A*STAR research institute in Singapore.
• Queen's University Belfast (BIOAID Programme)notableStrategic or Co-development PartnerAI-driven industrial biocatalysis doctoral training partnership (BIOAID) training scientists in AI and data-driven approaches for translational biocatalysis.
• CODE-M Doctoral ProgrammenotableStrategic or Co-development PartnerControl and Design of Bioengineered Microbial Cells and Systems training programme for microbial bioengineers tackling global challenges in health, prosperity and environmental sustainability.

Scale indicators10 records

Recent moves9 records

Expansion highlights7 records

Direct peers

• Francis Crick Institute: The Francis Crick Institute is a UK biomedical discovery research institute in London operating at similar scale (~1,500 staff, ~£100m+ annual research spend). It is directly comparable to MIB in being a multi-disciplinary life sciences research institute with similar funding model (UKRI grants, charitable support) and similar translational ambition.
• Wellcome Sanger Institute: The Wellcome Sanger Institute is a world-leading genomics and biodata research institute in Cambridge funded primarily by the Wellcome Trust. It is comparable to MIB in operating as a standalone genomics/biology research centre with similar research themes, similar funding model, and similar translational ambition into spin-out creation and industry partnerships.
• John Innes Centre: The John Innes Centre is a UK research institute in Norwich focused on plant and microbial science, including significant work on industrial biotechnology and bio-based chemicals. It is directly comparable to MIB in research themes (biocatalysis, sustainable bio-based products), funding model (BBSRC strategic grants), and translational focus (spin-out companies like Norwich Research Partners).
• Babraham Institute: The Babraham Institute is a UK life sciences research institute in Cambridge focused on signalling, epigenetics, and immunology. It is comparable to MIB in operating as a BBSRC-funded research institute of similar size, with similar research themes around fundamental bioscience and similar engagement model with industry.
• MRC Laboratory of Molecular Biology (LMB): The MRC LMB is a UK research institute in Cambridge focused on molecular biology, structural biology, and biochemistry. It is comparable to MIB in scale (~500 researchers), research themes (structural biology, enzyme mechanisms, protein engineering), funding model (MRC/UKRI grants), and Nobel-calibre research output.
• Whitehead Institute for Biomedical Research: The Whitehead Institute is a leading US biomedical research institute affiliated with MIT. It is comparable to MIB in operating as a focused biomedical research institute with strong faculty leadership model, similar research scale, and similar ambition around translating fundamental discoveries into commercial applications.

Regional players

• University of Edinburgh - Institute of Quantitative Biology, Biochemistry and Biotechnology: The University of Edinburgh's Institute of Quantitative Biology, Biochemistry and Biotechnology is a comparable UK academic research centre doing work in synthetic biology, industrial biotechnology, and bioengineering. It is comparable to MIB in research themes, academic positioning within a major UK research university, and similar funding model (BBSRC/EPSRC grants).

Broad incumbents

• Broad Institute of MIT and Harvard: The Broad Institute is a large-scale US biomedical and genomic research institute affiliated with MIT and Harvard. It is comparable to MIB in operating as a multi-disciplinary life sciences research powerhouse with significant computational biology capacity, similar AI-for-biology integration, and similar translational ambition into commercial applications.
• EMBL (European Molecular Biology Laboratory): EMBL is an intergovernmental research organisation for molecular biology with sites across Europe. It is comparable to MIB in operating as a multi-disciplinary life sciences research organisation with similar funding model (multi-government support), similar research themes (structural biology, bioinformatics), and similar training programmes (PhD and postdoc).

Emerging players

• Rosalind Franklin Institute: The Rosalind Franklin Institute is a UK national institute focused on developing new technologies to transform life science research. It is comparable to MIB in operating as a UK life sciences research organisation with similar funding model (UKRI), similar focus on technology development (instrumentation, methods), and similar translational ambitions.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/manchester-institute-of-biotechnology

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Manchester Institute of Biotechnology